Markers of Bone Turnover in Gaucher Disease: Modeling the Evolution of Bone Disease

被引:39
作者
van Dussen, L. [1 ]
Lips, P. [4 ]
Everts, V. E. [5 ]
Bravenboer, N. [4 ]
Jansen, I. D. C. [5 ,6 ]
Groener, J. E. M. [2 ]
Maas, M. [3 ]
Blokland, J. A. K. [7 ]
Aerts, J. M. F. G. [2 ]
Hollak, C. E. M. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Endocrine Sect, NL-1007 MB Amsterdam, Netherlands
[5] Vrije Univ Amsterdam, Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Cell Biol,Res Inst MOVE, NL-1081 LA Amsterdam, Netherlands
[6] Vrije Univ Amsterdam, Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Periodontol,Res Inst MOVE, NL-1081 LA Amsterdam, Netherlands
[7] Leiden Univ, Med Ctr, Div Nucl Med, Dept Radiol, NL-2300 RC Leiden, Netherlands
关键词
ENZYME REPLACEMENT THERAPY; SKELETAL INVOLVEMENT; AMINOHYDROXYPROPYLIDENE BISPHOSPHONATE; BIOCHEMICAL MARKERS; MINERAL DENSITY; IN-VITRO; MACROPHAGE; GLUCOCEREBROSIDASE; CHITOTRIOSIDASE; DEFICIENCY;
D O I
10.1210/jc.2011-0162
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Gaucher disease (GD) is a lysosomal storage disorder characterized by abundant presence of macrophages. Bone complications and low bone density are believed to arise from enhanced bone resorption mediated through macrophage-derived factors. Objective: The objective of the study was to investigate the relationship between bone turnover and bone complications in GD. Design: This was a retrospective cohort study and review of the literature. Patients: Forty adult type I GD patients were included in the study. Outcome Measures: Levels of the bone-resorption marker, type 1 collagen C-terminal telopeptide, and two bone-formation markers, N-terminal propeptide of type 1 procollagen and osteocalcin, were investigated in relation to clinical bone disease, measures of overall disease severity, and imaging data representing bone marrow infiltration. Results: Osteocalcin was decreased in 50% of our patients (median 0.35 nmol/liter, normal 0.4-4.0), indicating a decrease of bone formation. Type 1 collagen C-terminal telopeptide and N-terminal propeptide of type 1 procollagen were within the normal range for most patients. Osteocalcin concentration was negatively correlated to measures of overall disease severity and positively correlated with imaging data (correlation coefficient 0.423; P = 0.025), suggesting a relation with disease severity. A review of the literature revealed variable outcomes on bone resorption markers but more consistent abnormalities in bone formation markers. Two of three reports conclude that bone-formation parameters increase in response to enzyme therapy, but none describes an effect on bone-resorption markers. Conclusions: In contrast to earlier hypotheses, we propose that in GD patients, primarily a decrease in bone formation causes an imbalance in bone remodeling. (J Clin Endocrinol Metab 96: 2194-2205, 2011)
引用
收藏
页码:2194 / 2205
页数:12
相关论文
共 49 条
[1]   THE OCCURRENCE OF 2 IMMUNOLOGICALLY DISTINGUISHABLE BETA-GLUCOCEREBROSIDASES IN HUMAN SPLEEN [J].
AERTS, JMFG ;
DONKERKOOPMAN, WE ;
VANDERVLIET, MK ;
JONSSON, LMV ;
GINNS, EI ;
MURRAY, GJ ;
BARRANGER, JA ;
TAGER, JM ;
SCHRAM, AW .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1985, 150 (03) :565-574
[2]   Transglycosidase activity of chitotriosidase - Improved enzymatic assay for the human macrophage chitinase [J].
Aguilera, B ;
Ghauharali-van der Vlugt, K ;
Helmond, MTJ ;
Out, JMM ;
Donker-Koopman, WE ;
Groener, JEM ;
Boot, RG ;
Renkema, GH ;
van der Marel, GA ;
van Boom, JH ;
Overkleeft, HS ;
Aerts, JMFG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :40911-40916
[3]  
Allen MJ, 1997, QJM-MON J ASSOC PHYS, V90, P19
[4]  
Barak V, 1999, EUR CYTOKINE NETW, V10, P205
[5]  
Beutler E, 2001, METABOLIC MOL BASES, P3636
[6]   'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature [J].
Biegstraaten, M. ;
van Schaik, I. N. ;
Aerts, J. M. F. G. ;
Hollak, C. E. M. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 (03) :337-349
[7]   The human chitotriosidase gene - Nature of inherited enzyme deficiency [J].
Boot, RG ;
Renkema, GH ;
Verhoek, M ;
Strijland, A ;
Bliek, J ;
de Meulemeester, TMAMO ;
Mannens, MMAM ;
Aerts, JMFG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25680-25685
[8]   Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages [J].
Boven, LA ;
van Meurs, M ;
Boot, RG ;
Mehta, A ;
Boon, L ;
Aerts, JM ;
Laman, JD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (03) :359-369
[9]   METABOLISM OF GLUCOCEREBROSIDES .2. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHERS DISEASE [J].
BRADY, RO ;
KANFER, JN ;
SHAPIRO, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 18 (02) :221-&
[10]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED GLUCOCEREBROSIDASE IN GAUCHERS-DISEASE [J].
BRADY, RO ;
PENTCHEV, PG ;
GAL, AE ;
HIBBERT, SR ;
DEKABAN, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (19) :989-993